Risks for childhood bone cancer
Certain behaviours, substances or conditions can affect your risk, or chance, of developing cancer. Some things increase your risk and some things decrease it. Most cancers are the result of many risks. But sometimes cancer develops in people who don't have any risks.
There are 2 main types of bone cancer that develop in children. The types are osteosarcoma and Ewing sarcoma.
The chance that this cancer will develop is highest during the growth spurt in the teenage years. It occurs slightly more often in boys and in Black children (including children of African or Caribbean ancestry).
The following can increase the risk for osteosarcoma.
Certain inherited genetic syndromes @(Model.HeadingTag)>
Genetic syndromes are diseases or disorders caused by a change (mutation) in one or more genes. Having the following
Familial retinoblastoma is an inherited form of retinoblastoma, which is an eye cancer that occurs in children. Children with familial retinoblastoma have a higher risk of developing osteosarcoma and soft tissue sarcoma.
Li-Fraumeni syndrome is associated with an increased risk of developing certain types of cancers, including breast cancer, brain tumours, acute leukemias, soft tissue and bone sarcomas and adrenal cortical carcinomas.
Rothmund-Thomson syndrome causes skin rashes, thinning skin, small groups of blood vessels under the skin (telangiectasia) and bone problems. It increases the risk of developing osteosarcoma.
Werner syndrome causes the body to age very rapidly after puberty. It increases the risk for melanoma, bone, soft tissue and thyroid cancers.
Bloom syndrome causes shorter than average height, a high-pitched voice and a characteristic facial appearance. It is associated with an increased risk of developing cancer, including leukemia, lymphoma, breast, cervical, colon, stomach, laryngeal, non-melanoma skin cancers and osteosarcoma, as well as Wilms tumour. People with Bloom syndrome often develop several different types of cancer.
Diamond-Blackfan anemia affects the bone marrow. It also increases the risk for osteosarcoma.
Neurofibromatosis type 1 affects the nervous system. It affects the development and growth of neurons (nerve cells), causes tumours (neurofibromas) to grow on nerves and may cause other abnormalities in muscles, bones and skin. Sometimes cancerous tumours called malignant peripheral nerve sheath tumours may grow along the nerves. Neurofibromatosis type 1 increases the risk for neuroendocrine tumours, soft tissue sarcoma, osteosarcoma, brain tumours, leukemia and neuroblastoma.
Previous radiation therapy @(Model.HeadingTag)>
Children who had radiation therapy have a higher risk of developing osteosarcoma in the area that was treated. The risk is greater if higher doses of radiation therapy were used and if the child was treated at a young age. Osteosarcoma typically develops 5 to 20 years after radiation therapy.
Previous chemotherapy @(Model.HeadingTag)>
Children who had certain types of chemotherapy have a higher risk of developing osteosarcoma. This risk may be even higher if the child also received radiation therapy.
Certain bone diseases @(Model.HeadingTag)>
Children who have
No link to osteosarcoma @(Model.HeadingTag)>
Significant evidence shows no link between osteosarcoma and fluoride use or previous bone injury or fracture.
Ewing sarcoma @(Model.HeadingTag)>
Ewing sarcoma usually develops during the teenage years and is slightly more common in boys than in girls. It occurs more frequently in white children and is rare in Black children (including children of African or Caribbean ancestry).
There are no known risks for Ewing sarcoma.
Canadian Cancer Society | Société canadienne du cancer
Archer NP, Napier TS, Villanacci JF . Fluoride exposure in public drinking water and childhood and adolescent osteosarcoma in Texas. Cancer Causes and Control. 2016.
Roman E, Lightfoot T, Picton S, Kinsey S. Childhood cancers. Thun MJ, Linet MS, Cerhan JR, Haiman CA Schottenfeld D, eds.. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. 4th ed. New York, NY: Oxford University Press; 2018: 59.
Bassin, E. B., Wypij, D., Davis, R. B., et al . Age-specific fluoride exposure in drinking water and osteosarcoma (United States). Cancer Causes & Control. Springer; 2006.
Blakey K, Feltbower RG, Parslow RC, James PW, Gomez PB, et al . Is fluoride a risk factor for bone cancer? Small area analysis of osteosarcoma and Ewing sarcoma diagnosed among 0-49 year olds in Great Britain, 1980-2005. International Journal of Epidemiology. 2014.
Gorlick R, Janeway K, Marina N. Osteosarcoma. Pizzo PA, Poplack DG, eds.. Principles and Practice of Pediatric Oncology . 7th ed. Philadelphia, PA: Wolters Kluwer; 2016: 34:877–899.
Hawkins DS, Brennan BMD, Bolling T, Davidson DJ, Dirksen U, DuBois SG, Hogendoorn PCS, Lessnick SL. Ewing sarcoma. Pizzo PA, Poplack DG, eds.. Principles and Practice of Pediatric Oncology . 7th ed. Philadelphia, PA: Wolters Kluwer; 2016: 33:855–876.
International Agency for Research on Cancer (IARC). Volume 75: Ionizing Radiation Part 1: X- and Gamma (y)-Radiation, and Neutrons. 2000: http://monographs.iarc.fr/ENG/Monographs/vol75/mono75.pdf.
International Agency for Research on Cancer (IARC). Volume 100D: Radiation: a review of human carcinogens. 2011: http://monographs.iarc.fr/ENG/Monographs/vol100D/mono100D.pdf.
Levy M, and Leclerc BS . Fluoride in drinking water and osteosarcoma incidence rates in the continental United States among children and adolescents. Cancer Epidemiology. Elsevier; 2012.
Miller RW, Boice JD, Jr & Curtis RE . Bone cancer. Schottenfeld, D. & Fraumeni, J. F. Jr. (eds.). Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006: 48: pp. 946-958.
Ross, J.A. & Spector, L.G . Cancers in children. Schottenfeld, D. & Fraumeni, J. F. Jr. (Eds.). Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006: 65: 1252-1268.
Wang LL, Yustein J, Louis C, et al . Solid tumors of childhood. DeVita VT Jr, Lawrence TS, & Rosenberg SA. Cancer: Principles & Practice of Oncology. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011: 123: pp. 1760-92.